The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Narrative Review: The U.S. Pharmacopeia and Model Guidelines for Medicare Part D Formularies

The USP Model Guidelines Expert Committee and U.S. Pharmacopeia Staff*
[+] Article, Author, and Disclosure Information

From the U.S. Pharmacopeia, Rockville, Maryland.

Acknowledgment: The authors thank Stefan Schuber, PhD, Director, Scientific Reports at USP, for editorial assistance with this manuscript.

Grant Support: The CMS and USP entered into Cooperative Agreement No. 18-C-92305/3-01 in support of the development of the Model Guidelines.

Potential Financial Conflicts of Interest: The work of USP's MGEC was carried out according to USP's strict rules regarding conflict of interest. Dr. Braden has been employed by AdvancePCS (now Caremark), which offers a Medicare Part D prescription drug plan, and is employed by Mercy Care of Arizona, a fully qualified Medicare special needs plan. Dr. Finkelstein has provided health economic consulting to pharmaceutical companies through Thomson Medstat Group and has received an educational grant from Merck, both for topics unrelated to this manuscript. Dr. Horn is an employee of Pfizer and holds stock in Johnson & Johnson. Dr. Kirking has consulted for Wyeth and has received grants from Wyeth, AstraZeneca, Merck, and Pfizer. Dr. Westrick served as a consulting medical advisor to PBM from 1997 to 2002 and received honoraria from Pfizer and Interactive Forums in 2004 and 2005.

Requests for Single Reprints: Stefan Schuber, PhD, U.S. Pharmacopeia, 12601 Twinbrook Parkway, Rockville, MD 20852-1790; e-mail, sps@usp.org.

Current Author Addresses: Dr. Williams, Ms. King, Ms. Penn, Dr. Perfetto, Ms. Singh, and Mr. Zeruld: U.S. Pharmacopeia, 12601 Twinbrook Parkway, Rockville, MD 20852-1790.

Dr. Abernethy: National Institute on Aging, 5600 Nathan Shock Drive, Baltimore, MD 21224.

Dr. Bielory: University of Medicine and Dentistry of New Jersey–New Jersey Medical School, 90 Bergen Street, DOC, Suite 4700, Newark, NJ 07103.

Dr. Blum: 25 Spruce Drive, East Hills, NY 11575-2331.

Dr. Braden: 2800 North Central Avenue, Phoenix, AZ 85004.

Dr. Calis: National Institutes of Health, 10 Center Drive (MSC 1196), Building 10, Room 1S-259, Bethesda, MD 20892.

Dr. Campen: Kaiser Permanente Pharmacy Operations, 1800 Harrison Street, 13th Floor, Oakland, CA 94612.

Dr. Finkelstein: MIT Sloan School of Management, 38 Memorial Drive, E56-390, Cambridge, MA 02139-4307.

Dr. Foster: University of Kentucky Medical Center, 907 Rose Street, Suite 231F, Lexington, KY 40536-0082.

Dr. Horn: Pfizer Inc., 235 East 42nd Street, New York, NY 10017.

Dr. Kirking: University of Michigan College of Pharmacy, 428 Church Street, Ann Arbor, MI 48109-1065.

Dr. Murray: University of North Carolina, CB-7360, Beard Hall, Room 205-R, Chapel Hill, NC 27599-7360.

Ms. Rucker: AARP, 601 E Street, NW, B-6 433, Washington, DC 20049.

Dr. Schwartzberg: American Medical Association, 515 North State Street, Chicago, IL 60610.

Dr. Shepherd: University of Texas Health Science Center, 7703 Floyd Curl Drive, 5.102 MCD, Mail Code 6205, San Antonio, TX 78229-3900.

Dr. Strnad: Health Canada, 1600 Scott Street, Holland Cross, Tower B, 2nd Floor, AL 3102C3, Ottawa, Ontario K1A 1B6, Canada.

Dr. West: Northwestern University Feinberg School of Medicine, Department of Dermatology, 675 North St. Clair Street, Suite 19-200, Chicago, IL 60611.

Dr. Westrick: University of Massachusetts Memorial Health Care, One Biotech Park, 365 Plantation Street, Worcester, MA 01605-2376.

Ann Intern Med. 2006;145(6):448-453. doi:10.7326/0003-4819-145-6-200609190-00008
Text Size: A A A

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 includes a provision directing the Secretary of the U.S. Department of Health and Human Services to request that the U.S. Pharmacopeia (USP) develop a list of categories and classes (the USP Model Guidelines) that can be used by prescription drug plans in developing their formularies for the Part D prescription drug benefit. The Centers for Medicare & Medicaid Services (CMS) used the Model Guidelines and USP's related listing, termed the Formulary Key Drug Types, to evaluate prescription drug plan formularies submitted by prescription drug plan sponsors intending to provide the new Part D benefit. This article recounts how USP's all-volunteer Model Guidelines Expert Committee developed the USP Model Guidelines and Formulary Key Drug Types, working under a cooperative agreement with CMS in response to the Secretary's request. The Model Guidelines and Formulary Key Drug Types are updated annually to reflect advances in evidence-based medicine, thereby offering timely guidance to CMS and to prescription drug plans based on USP's demonstrated expertise in setting standards.

*For members of the USP Model Guidelines Expert Committee and the U.S. Pharmacopeia staff who contributed to this manuscript, see Appendix 1.


Grahic Jump Location
U.S. Pharmacopeia (USP) and the Medicare prescription drug benefit.
Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.